Skip to main
PHGE

BiomX Inc. (PHGE) Stock Forecast & Price Target

BiomX Inc. (PHGE) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BiomX is a promising biotech company that has a positive outlook due to its strong financial standing, with a cash balance of $8.1 million and a recent increase in share price through a reverse split. The company has made significant progress in addressing the FDA's concerns regarding its lead assets, BX211 and BX004, and received new feedback acknowledging the unmet need for treatments targeting P. aeruginosa infection in CF. Despite risks, the company's potential to attain higher market penetration and expand its valuation through additional indications and partnerships could lead to significant upside and achieving our target price of $26.

Bears say

BiomX is facing potential challenges with its FDA clinical trial approval for BX004 due to unresolved concerns surrounding the use of a third-party nebulizer device. Additionally, while the company has received positive FDA feedback for its fixed multi-phage cocktail, BX011, for the treatment of diabetic foot infections, they may face obstacles in reaching their projected market penetration and obtaining additional indications for its use. Finally, the FDA's recommended endpoints for the clinical trial of BX011 may require a large number of patients, which could be a potential barrier to achieving their target price.

BiomX Inc. (PHGE) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BiomX Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BiomX Inc. (PHGE) Forecast

Analysts have given BiomX Inc. (PHGE) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BiomX Inc. (PHGE) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BiomX Inc. (PHGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.